In patients who have had a mild stroke or a transient ischemic attack (TIA), dual antiplatelet medication has been demonstrated to minimize the risk of recurrent stroke. The patient population in the POINT (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke) trial consisted of 54% males, and the average patient age was 66.3 years. There were 4,881 patients in the research, with 41% of them receiving no pretreatment antiplatelet medication.
During the 90-day follow-up, the primary outcome was ischemic stroke. In contrast, the secondary outcome was the risk of significant bleeding, hospitalization or prolongation of existing hospitalization, or death from hemorrhage.
Ischemic stroke occurred in 6% of those who received antiplatelet therapy and 5% of those who did not receive antiplatelet therapy in the study. Study author Mohammad Anadani, MD, said, “In this study, we found that pretreatment antiplatelet therapy was not associated with the risk of recurrent ischemic stroke. More importantly, the effect of DAPT appeared to be consistent regardless of pretreatment antiplatelet therapy. Our study adds additional evidence that patients with minor stroke or TIA should be started on DAPT irrespective of their pretreatment antiplatelet status.”
Conclusion: According to the researchers, antiplatelet therapy did not increase the risk of ischemic stroke or severe hemorrhage. Furthermore, the effect of dual antiplatelet medication on the risk of recurrent ischemic stroke was similar among patients who were on antiplatelet therapy before to randomization versus those who were not.